Olmesartán/Amlodipino/Hidroclorotiazida Aurovitas (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan Medoxomil, the active ingredient in Olmesartán/Amlodipino/Hidroclorotiazida Aurovitas, is an angiotensin II receptor blocker presented as a fixed‑dose oral tablet for oral use. It is used to lower blood pressure in adults with hypertension, often in combination with a calcium‑channel blocker and a thiazide diuretic for enhanced effect. GNH USA supplies Olmesartán/Amlodipino/Hidroclorotiazida Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan/Amlodipine/Hydrochlorothiazide is a fixed‑dose combination antihypertensive that targets the renin‑angiotensin system, calcium channels and diuretic pathways. - Hypertension: provides synergistic reduction of systolic and diastolic blood pressure in adults. - Hypertensive chronic kidney disease: helps control blood pressure while reducing proteinuria progression. - High cardiovascular risk patients: lowers blood pressure to decrease the risk of stroke, myocardial infarction and other vascular events.

Common Side Effects: - Dizziness: light‑headed sensation, especially after standing. - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or lower legs. - Flushing: transient warmth and redness of the skin. - Fatigue: general feeling of tiredness. - Nausea: mild stomach upset.

Serious or Rare Side Effects: - Angioedema: rapid swelling of face, lips or throat. - Severe hypotension: markedly low blood pressure causing faintness. - Electrolyte imbalance: abnormal potassium or sodium levels. - Acute renal impairment: sudden decline in kidney function. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain.

Before initiating therapy, clinicians should consider several safety measures. - Monitor blood pressure: adjust dosage if target levels are not achieved. - Assess renal function: especially important due to the diuretic component. - Check electrolytes: watch for potassium and sodium disturbances. - Use with caution in severe hepatic impairment: drug metabolism may be altered. - Contraindicated in pregnancy: risk of fetal toxicity. - Store at room temperature: keep in the original packaging, protect from moisture and light.

Olmesartan/Amlodipine/Hydrochlorothiazide may interact with several medicines. Major Interactions (Avoid): - ACE inhibitors or other ARBs: increased risk of hyperkalemia and renal dysfunction. - Potassium‑sparing diuretics: may cause dangerous hyperkalemia. - NSAIDs: can blunt antihypertensive effect and impair renal function. Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise amlodipine concentrations. - CYP3A4 inducers (e.g., rifampin): may reduce amlodipine efficacy. - Beta‑blockers: additive hypotensive effect may require dose adjustment.